An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Anti-tumor Efficacy and Safety of GM-CSF (Sargramostim, Leukine) Associated With Rituximab (MabThera) in Patients With Follicular Non Hodgkin's Lymphoma With no Prior Treatment

Trial Profile

An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Anti-tumor Efficacy and Safety of GM-CSF (Sargramostim, Leukine) Associated With Rituximab (MabThera) in Patients With Follicular Non Hodgkin's Lymphoma With no Prior Treatment

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Rituximab; Sargramostim
  • Indications Non-Hodgkin's lymphoma
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Jul 2012 Companies added in the association field as reported by EudraCT.
    • 04 Jul 2012 Actual initiation date 19 Sep 2008 added as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top